Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma
María Santos(Spanish National Cancer Research Centre), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Javier Lanillos(Spanish National Cancer Research Centre), Juan María Roldán‐Romero(European Bioinformatics Institute), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Geòrgia Anguera(Hospital de Sant Pau), Cristina Montero‐Conde(Spanish National Cancer Research Centre), Alberto Cascón(Spanish National Cancer Research Centre), Núria Laínez(Complejo Hospitalario de Navarra), Luis Robles(Hospital Universitario 12 De Octubre), Miguel Ángel Climent(Radboud University Nijmegen), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Eduardo Caleiras(Spanish National Cancer Research Centre), Susana Hernando(Hospital Universitario Fundación Alcorcón), Jesús García-Donás(Universidad San Pablo CEU)
Cited by 22
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528